Eculizumab

Therapeutic indications

Eculizumab is indicated for:

Paroxysmal nocturnal haemoglobinuria (PNH)

Population group: only adults (18 years old or older)

Eculizumab is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

600-900 mg once a week

Atypical haemolytic uremic syndrome (aHUS)

Population group: only adults (18 years old or older)

Eculizumab is indicated in adults and children for the treatment of atypical haemolytic uremic syndrome (aHUS).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

900-1,200 mg once a week

Generalized myasthenia gravis (gMG)

Population group: only adults (18 years old or older)

Eculizumab is indicated in adults for the treatment of refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

900-1,200 mg once a week

Neuromyelitis optica spectrum disorder (NMOSD)

Population group: only adults (18 years old or older)

Eculizumab is indicated in adults and children for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

900-1,200 mg once a week

Paroxysmal nocturnal haemoglobinuria (PNH)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Eculizumab is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

300-1,200 mg once a week

Atypical haemolytic uremic syndrome (aHUS)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Eculizumab is indicated in adults and children for the treatment of atypical haemolytic uremic syndrome (aHUS).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

300-1200 mg once a week

Contraindications

Eculizumab is contraindicated in the following cases:

Neisseria meningitidis infection

Meningococcal infectious disease

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈